Table 2.

GSH, MDA, SOD, CAT, and NO in lung homogenate of control (C), diabetic (D), diabetic + (0.25 mg/kg/day) safranal-treated (D + S1), diabetic + (0.5 mg/kg/day) safranal-treated (D + S2), and diabetic + (0.75 mg/kg/day) safranal-treated (D + S3) rats following 4 weeks of study.

Lung	C	D	D + S1	D + S2	D + S3
MDA (nmol/mg protein)	4.12 ± 0.86	14.61 ± 0.88***	11.56 ± 0.54∗∗∗,+	9.50 ± 0.48∗,+++	7.92 ± 0.36+++,##
GSH (nmol/mg protein)	21.60 ± 0.92	13.88 ± 0.28***	17.24 ± 0.40∗∗∗,+++	18.74 ± 0.25∗∗,+++	21.16 ± 0.48+++,###,×
SOD (U/mg protein)	8.40 ± 0.43	2.00 ± 0.35***	4.00 ± 0.31∗∗∗,++	5.40 ± 0.43∗∗∗,+++	7.88 ± 0.26+++,###,××
CAT (U/mg protein)	6.16 ± 0.35	2.84 ± 0.28***	4.12 ± 0.22∗∗∗,+	5.11 ± 0.26+++	5.68 ± 0.28+++,##
NO (μmol/L)	19.41 ± 3.88	86.00 ± 1.70***	71.00 ± 2.91∗∗∗,+	49.61 ± 3.32∗∗∗,+++,###	30.41 ± 3.23+++,###,××

Each measurement has been done at least in triplicate and the values are the means ± SEM for eight rats in each group.

Statistical significance for the difference between the data of control versus other groups: *P < 0.05, **P < 0.01, ***P < 0.001.

Statistical significance for the difference between the data of diabetes versus treated groups: ⁺ P < 0.05, ⁺⁺ P < 0.01, ⁺⁺⁺ P < 0.001.

Statistical significance for the difference between the data D + S1 versus D + S2 and D + S3 (^## P < 0.01, ^### P < 0.001).

Statistical significance for the difference between the data between D + S2 versus D + S3 (^× P < 0.05, ^×× P < 0.01).